Aims: Families with 10-12-year-old schoolchildren were informed about and asked to participate in a study to identify children with hyperlipoproteinemia. We hypothesised that children and families with familial blood lipid abnormalities, specifically those with familial hypercholesterolemia (FH) and familial combined hyperlipidemia (FCHL), could be identified by the child's apolipoprotein B level exceeding the 95th percentile. Methods: Written information and consent was distributed to the families. Families whose child had an apoB concentration exceeding the 95th percentile were further examined. Children and parents were divided into normal, high and very high low density lipoprotein cholesterol (LDLC) groups. In adults a high LDLC level was defined as 
Introduction
Atherosclerosis may begin early in life when intermediate and low-density lipoproteins (LDL) are deposited in the artery walls (1) . The evidence of the importance of LDL comes from experimental, epidemiological and ge-netic sources. Individuals with familial hypercholesterolemia (FH) and familial combined hyperlipidemia (FCHL) are at high risk and account for about 15% of individuals suffering premature coronary heart disease (CHD) (2, 3) . The subsequent risk of CHD is, however, also influenced by life style, multiple genes and gene-environment interactions (4) .
The measurement of plasma apolipoprotein B (apoB), allows assessment of the total number of atherogenic particles containing apoB (5) . We thus hypothesised that families at high risk of CHD might be identified by the child's apoB concentration exceeding the 95th percentile and that family members with a high-risk constitution should ideally be informed before lifestyle factors associated with additional CHD risk are established.
Material and Methods
Written information and consent forms were distributed to parents of 10-12-year-old school children. The families were informed that risk factors for certain hereditary cardiovascular diseases in adulthood might be identified already in childhood and that knowledge of the high-risk constitution offers an opportunity to prevent premature CHD. The child and parents were also informed that the lipoprotein was analysed from a capillary blood test. It was stressed that participation in the study was voluntary. There were three response alternatives:
1.Yes, we want our child to participate. 2. No, we don't want to participate. 3. We want supplementary information. The written detailed supplementary information about the scientific background of the study was delivered upon request by the school-nurse. The information and consent forms were distributed to 2,855 families with a 10-12-year-old school child.
In the first step apoB was determined from the child's capillary blood. If the apoB concentration exceeded the 95th percentile, the child and his/her parents were informed and offered analyses of their blood lipids including lipoprotein (a) [Lp(a)], followed by further information by the doctors responsible for this study.
Capillary blood samples for apoB analyses were obtained non-fasting. Blood samples from children with apoB concentrations exceeding the 95th percentile and their parents were collected after an overnight fast and were analysed the same day. Serum concentrations of apoB were measured by an immunoturbidimetric method, CV < 2%, with reagents from Dacopatts, Copenhagen, Denmark. Concentrations of total cholesterol (TC) and triglycerides (TG) were determined using the Kodak x700 system, CV < 3%. Before measurement of high-density lipoprotein cholesterol (HDLC), lipoprotein was precipitated with dextran sulphate and MgCl2. The CV of HDLC measurements was 4%. The LDLC concentrations were calculated using the Friedewald formula. Serum Lp(a) concentrations were measured by a radioimmunoassay (Pharmacia, Sweden), CV 2% at 180 mg/l, details of which have previously been described (6) . Obesity is defined as BMI above 24 in 10-12-year-old children and above 30 in adults (7) Hemoglobin A1c (HbA1C) was analysed in obese children, normal range 3.6-5.0%.
The study was approved by the Ethical Committee at Lund University.
Results
Families of 2,855 children, were informed about the study and asked to participate. Of the 2,855 informations and questionnaires distributed, 2441 were returned, 2186 agreeing to participate in a written informed consent. The normal age and sex distribution of apoB was determined from the first 255 blood samples. No age-dependent difference of the apoB concentration was found between 10, 11 and 12-year-olds. A sexdependent difference was established. The mean (± SD), 95th percentile, apoB concentration for 10-12year-old boys (n = 124) was 0.68 (0.16), 0.98 g/l and girls (n = 131) 0.75 (0.17), 1.07 g/l. The upper normal level for adult males is 1.40, females 1.30 g/l (6). An apoB level above the 95th percentile was revealed in 131 children (68 boys, 63 girls) of the 2,186 schoolchildren willing to participate ( Table 1 ). The families of these children were informed about the apoB test results and invited to further oral information, physical check-up and blood lipid analyses. Of the invited families, 22 declined to participate.
Guided by the LDLC test results of the children, the families were divided into three groups (Table 2) Table 1 . Children taking part in the apolipoprotein B study.
The LDLC concentration of the respective parent was graded according to NCEP recommendations (8) 
HyperapoB children with LDLC ≤ 3.4 mmol/l
The LDLC levels were within normal limits in 28 (25%) of the 109 children with apoB > 95th percentile. In 20 of these families the LDLC test results of the parents were normal. In one parent of two families a high and in one parent of three families a very high LDLC level was found. In one family a parent was treated for hypercholesterolemia and in another a parent had hypertriglyceridemia ( Table 2) . One child was adopted.
HyperapoB children with LDLC > 3.4-4.1 mmol/l
A high LDLC concentration was found in 52 of 109 hyper apoB children, 48%, ( Table 2 ). In 26 of these families the LDLC levels of the parents were normal. In 10 families one parent and in two families both parents had a high LDLC concentration and in two, one parent had hypertriglyceridemia. In three other families, one parent had high LDLC and the other hypertriglyceridemia. Very high levels of LDLC, > 4.9 mmol/l, were revealed in one or both parents of 11 families (both father and mother had very high LDLC in two families). The father in one family was being treated for hypercholesterolemia and had undergone by-pass operation.One child had foster-parents.
HyperapoB children with LDLC > 4.1 mmol/l
A very high LDLC concentration was established in 29 children, 27% ( Table 2 ). The abnormality was caused by hypothyroidism in two girls, the LDLC dropping to normal levels in one of them after treatment. Ten children had parents with normal blood lipid levels. In six families, one parent had high LDLC concentration. In nine of the families very high LDLC was found in one parent. One parent was already diagnosed and treated for FH and another with drug problems only allowed analysis of TC (10.25 mmol/l). Two parents had hypertriglyceridemia. One child was adopted.
The thyroid-stimulating hormone, TSH, test which was measured in all children with abnormal LDLC concentrations, was normal in all except the two girls as accounted for above. Of 109 hyperapoB children, 23 (21%) were obese, all of them had normal HbA1c test results.
Lp(a) concentration was determined in all children having blood lipid analyses. Of 109 children 35 had a Lp(a) test result > 300 mg/l. Of the 29 children with very high LDLC, 10 had an abnormal Lp(a) level.
The individual LDLC levels of families with a child and parent in the very high LDLC concentration group are given in Table 3 . In this table the occurrence of premature CHD in relatives are recorded (premature CHD defined as CHD before 60 years of age).
Children with hyperapoB and high LDLC levels having a hyperapoB parent with either LDLC above 4.9 or TG above 3.6 mmol/l are presented in Table 4 .
Discussion
There are certain both pathophysiological and methodological advantages speaking in favour of apoB analysis (9) . In addition fasting is not needed before blood sampling. Each LDL and VLDL particle contains one molecule of apoB. Thus plasma apoB equals the total number of atherogenic particles. Atherosclerotic vascular lesions start to develop early in life and are related to childhood serum lipoprotein levels (1, 10 ). An inverse re- N: Number 1 One adopted child. 2 One child with foster-parents. 3 Including parents on statin therapy. 4 Two children suffered hypothyroidism (LDLC 6.5 and 5.1 mmol/l), parents were excluded. lation between LDLC concentration and brachial artery distensibility was observed in 9-14-year-old children (11) . Together with other recent observations the study suggests that CHD risk factors affect vascular structure and function in childhood and subsequent development of future CHD (11, 12) . Despite the effectiveness of medical intervention on CHD morbidity it is likely that prevention of an inappropriate life-style in adolescence is essential, particularly for those at high CHD risk (13, 14) . In previous studies of α1-antitrypsin deficiency and obesity in childhood we have demonstrated that smoking, diet and physical activity may be favourably affected by intervention and advice during adolescence (7, 15) . Two prospective intervention studies, the STRIP trial in early childhood and the DISC trial in pre-puberty and puberty, showed that dietary fat restriction and other risk factor controls can be performed safely (16, 17) . In this study we addressed a key issue of the high-risk CHD strategy, how to find children at greatest risk, in particular those with hereditary hyperlipoproteinemia. A considerable likelihood of FH is evident in children who have LDLC concentrations above about twice the normal LDLC level, i.e. above 4.9 mmol/l (18) . Six of the children (Table 3) fulfil that criterion and also have a parent with a very high LDLC level (family 1-6). In five out of six of these families a first degree relative of the parent was found with premature CHD. Thus a high probability of FH was detected in 1/360 families. In the preliminary Swedish and a Danish studies using dried blood on filter paper, despite methodological problems, again an incidence of FH of 1/300-1/350 was indicated (19, 20) . None of the children or parents in the 11 families with very high LDLC levels were obese. Mutations in the LDL receptor gene and the LDL receptor-binding region of the apoB gene are both known to increase LDLC levels substantially and thus the risk of CHD (2, 21) . Heterozygous FH with about doubled LDLC levels occur in 1/500 of the general population, the Swed- ish and Danish studies indicating a higher incidence in the Scandinavian populations. Heterozygosity for familial defective apoB 100 increases LDLC level by 50-100% and occurs in 1/1,000 of the population. Hundreds of different mutations have been found in FH while mainly one mutation is responsible for familial defective apo-B (22) . Familial combined hyperlipidemia is characterised by an overproduction of apo B and VLDL, often diminished HDL levels and small dense LDL particles. In children with FCHL, hyperlipidemia may not be evident until later in life (3, 23) . From a genetic point of view FCHL is complicated, involving many genes and gene-environment interactions (21) . If we assume that FCHL is inherited as originally described in an autosomal dominant pattern with a 1% frequency in the general population, then about 20 such families should be found among the families with a hyperapoB child with normal-high LDLC and a parent with abnormal apoB, LDLC and/or TG levels (24). We did not have access to extended lipid profiles and pedigrees of each family. However, families 7-27 have blood lipid abnormalities and hyperapoB indicating FCHL. Of the 20 families, nine individuals were obese and five relatives had suffered premature CHD.
The usefulness of apoB in studying children with high LDLC was addressed in a Spanish study of 267 children with hyper LDLC (25) . About half had a parent with dyslipoproteinemia. The types of dyslipoproteinemia in 24 children having both elevated LDLC and apoB were FH 50%, FCHL 46% and polygenic hypercholesterolemia 4%. The study, however, was from a referral centre. Few parents were aware of their high-risk LDLC profile before being identified through their child with hyperapo B. LDLC is the focus of the last adult treatment panel from NCEP (National Cholesterol Education Program). The opinion that high LDLC is the major cause of CHD is based upon multiple evidence, the last being the delipidisation of human plaque by statin treatment (26) . The recommendation is that all adults from 20 years of age should be tested for blood lipid disorders. If this recommendation is widely accepted, children with hereditary hyperlipidemia may be identified by knowledge of the parent's blood lipid profile. Screening of all young individuals for serum cholesterol along with cardiovascular risk factor profile is recommended considering results from the Bogalusa Heart Study (27) .
In a recent study we have identified potential CHD highrisk children from the occurrence of premature CHD in Table 4 . HyperapoB children and parents with LDLC 3.4-4.1 mmol/l and four parents LDLC > 4.9 mmol/l or/and TG > 3.6 mmol/l. LDLC two level 2 years after identification within brackets. TC, HDLC, LDLC and TG mmol/l.
Fam
Child 1st or 2nd degree relatives (28) . In the present study two thirds of the children with very high LDLC and one fourth with potential FCHL had a family history of premature CHD. Of interest is that 20% of the hyperapoB children were obese. We know from earlier studies that BMI correlates significantly with apoB (29) . These two approaches will thus partially identify different populations of individuals with potential high-risk of CHD. Many affected FH individuals may have normal life-spans (30, 31) . These observations indicate that even in families with FH or FCHL, other genetic and/or environmental factors modulate the cardiovascular risk. Individual regimens may accordingly be developed to prevent CHD in families with hereditary hyperlipoproteinemias. In conclusion this study indicates that it is possible to identify families with familial hyperlipoproteinemia by apo B testing of 10-12-year-old children. Such an approach is an opportunity for primary CHD prevention in families at highest risk.
